EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

A retrospective analysis for early-stage non-endometrioid endometrial cancers

Eunkyoung Lee, Won Kyung Cho, Won Park, Jeong-Won Lee, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim

Radiation Oncology Journal · 30.06.2026 · 44 (2) · 90-96

DOI: 10.3857/roj.2025.00724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Oncology Journal, erschienen am 30.06.2026. Verfasst von Eunkyoung Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to investigate treatment outcomes and explore optimal adjuvant treatment options for patients with early-stage uterine serous carcinoma (USC) and clear cell carcinoma (CCC).Materials and Methods: We retrospectively reviewed the records of 63 patients diagnosed with stage I–II (2009 International Federation of Gynecology and Obstetrics [FIGO]) USC or CCC. Survival outcomes were estimated using the Kaplan-Meier method, and comparisons between groups were performed with the log-rank test.

Results

Among the 63 patients, 36 (57.1%) had USC and 25 (39.7%) had CCC. According to the revised 2023 FIGO staging system, 23 patients (36.5%) were stage IC, and 40 (63.5%) were stage IIC. Adjuvant treatment included no adjuvant therapy (23.8%), chemotherapy alone (39.7%), radiotherapy alone (28.6%), and combined chemotherapy plus radiotherapy (8.0%). After a median follow-up of 54 months (range, 5 to 227 months), the 5-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 89.5% and 85.7%, respectively. Patients with CCC had a 5-year PFS of 95.8% and OS of 92.3%, whereas those with USC had a 5-year PFS of 85.1% and OS of 81.4%. Most recurrences (7/63, 11.1%) were distant, occurring predominantly in USC cases (6/7) and 2023 stage IIC (7/7).

Conclusion

In this retrospective study, early-stage USC and CCC had very favorable PFS and survival outcomes. Thus, future randomized clinical trial or large cohort study is necessary to determine the optimal adjuvant treatments in these patients.

Schlagwörter

Stichwörter der Autor:innen

Endometrial neoplasmsNeoplasm stagingPrognosisRetrospective studiesSurvival analysis

Autor:innen und Institutionen

  • Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Lee, E., Cho, W. K., Park, W., Lee, J. W., Lee, Y. Y., Choi, C. H., & Kim, T. J. (2026). A retrospective analysis for early-stage non-endometrioid endometrial cancers. Radiation Oncology Journal, 44(2), 90-96. https://doi.org/10.3857/roj.2025.00724

Vancouver

Lee E, Cho WK, Park W, Lee JW, Lee YY, Choi CH, et al. A retrospective analysis for early-stage non-endometrioid endometrial cancers. Radiation Oncology Journal. 2026;44(2):90-96. doi:10.3857/roj.2025.00724

BibTeX
@article{Lee2026,
  author = {Lee, Eunkyoung and Cho, Won Kyung and Park, Won and Lee, Jeong-Won and Lee, Yoo-Young and Choi, Chel Hun and Kim, Tae-Joong},
  title = {A retrospective analysis for early-stage non-endometrioid endometrial cancers},
  journal = {Radiation Oncology Journal},
  year = {2026},
  volume = {44},
  number = {2},
  pages = {90--96},
  doi = {10.3857/roj.2025.00724}
}
Kostenlos starten →